tldrdailynews.com logo

Grail's Galleri multi-cancer test misses primary endpoint in NHS study, fueling skepticism

1 min read
Source: statnews.com
Grail's Galleri multi-cancer test misses primary endpoint in NHS study, fueling skepticism
Photo: statnews.com
TL;DR

Grail's Galleri blood test for early cancer detection failed to meet its primary endpoint in a large NHS-backed study, renewing questions about its clinical utility despite some detected benefits. Grail reported selling 185,000 tests in 2025 for $136.8 million, and its stock fell about 47% after hours following the setback.

Topics:businessbiotech#biotech#cancer-detection#diagnostics#galleri#grail#nhs
Share this article
  1. Key study of Grail’s cancer detection test fails in setback for company  statnews.com
  2. GRAIL Q4 Earnings Call Highlights  Yahoo Finance
  3. Grail shares plunge on mixed cancer trial data and steep losses  Investing.com
  4. GRAL Stock Slumps 48% After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses  Stocktwits
  5. GRAL: Strong commercial growth and positive trial results drive optimism for 2026 and beyond  TradingView

Want the full story? Read the original reporting

Read on statnews.com